Five life sciences technology predictions for 2027

Why governed, connected technology will turn AI ambition into operational trust.

Life sciences does not need another year of impressive technology demonstrations. It needs a more reliable way to translate scientific progress into repeatable execution. As pharmaceutical, biotechnology, and medical device organizations plan for 2027, the decisive question will be less “What can this technology generate?” and more “Can we trust it inside the processes that matter?”

My central prediction is that 2027 will favor connected, governed technology over isolated experimentation. AI will remain prominent, but its business value will depend on controlled information, reliable partner networks, resilient applications, and disciplined communication.

Predictions at a glance

  • Governed AI agents will move into regulated knowledge work
  • The connected evidence lifecycle will become more valuable than another document repository
  • Supply chain intelligence will shift from visibility to governed exception orchestration
  • Cyber resilience and software assurance will converge around continuity of critical operations
  • Omnichannel engagement will mature into governed, context-aware communication

1. Governed AI agents will move into regulated knowledge work

In 2027, I expect life sciences organizations to shift AI investment from general-purpose chat interfaces toward narrowly scoped agents embedded in clinical, regulatory, and quality workflows. Early opportunities will include finding approved source material, comparing document versions, assembling review packages, and identifying missing information for human assessment. The practical objective will be to reduce the work surrounding expert judgment—not to delegate scientific accountability to a model.

The regulatory direction supports this measured approach. In January 2026, FDA and EMA published ten guiding principles for good AI practice in drug development, emphasizing context of use, data governance, risk-based performance assessment, and lifecycle management. These principles are a foundation for good practice and future guidance, not a blanket authorization for autonomous decision-making. Expect more deployment discussions to begin with permissions, traceability, and review requirements rather than model size.

2. The connected evidence lifecycle will become more valuable than another document repository

My second prediction is that modernization programs will increasingly be judged by how well they preserve relationships between records across the product lifecycle. Storing a document is necessary; understanding how each record supports a study, product, submission, manufacturing process, or change is more valuable. In 2027, the emphasis will move toward persistent metadata, controlled reuse, and documented relationships between evidence and the activities it supports.

Consider a manufacturing change. Its significance may extend beyond a revised procedure to specifications, training materials, validation documentation, and regulatory commitments. A connected information layer can help teams identify those dependencies and coordinate review. This is not an argument for replacing every laboratory, clinical, quality, or regulatory application with one platform. It is an argument for making authoritative content accessible and understandable across application boundaries while preserving ownership and control.

3. Supply chain intelligence will shift from visibility to governed exception orchestration

In 2027, the next meaningful step in life sciences supply chain digitization will be connecting partner transactions to coordinated exception handling. Knowing that a shipment is delayed is useful. Understanding which production schedule, clinical supply requirement, or customer commitment may be affected—and routing that information to the right decision-maker—is substantially more useful.

I expect organizations to place greater emphasis on digital connections among manufacturers, contract development and manufacturing organizations, suppliers, distributors, and logistics providers. Electronic data interchange (EDI) and application programming interface (API) integration will supply the transactional foundation; contextual analytics and bounded automation will help prioritize discrepancies and escalate issues. The limiting factor will often be partner-data completeness and timeliness, not the sophistication of the dashboard. Autonomous product disposition or release should not be confused with automating an alert or gathering supporting records.

4. Cyber resilience and software assurance will converge around continuity of critical operations

My fourth prediction is that life sciences organizations will increasingly manage cybersecurity, application quality, and IT operations as connected disciplines. A critical service can fail because of an attack, a defective release, an integration problem, or a configuration change. From the perspective of a trial team or manufacturing operation, the immediate business questions are similar: What is affected, can the information be trusted, and how can service be restored safely?

Cybersecurity, application quality, and IT operations will increasingly converge around a shared priority: continuity of critical operations. AI-assisted development will make this coordination more important: faster code generation is not a substitute for requirements traceability, testing, security assessment, and release authorization. Similarly, detecting an anomaly is only the beginning of a response; recovery must address both availability and confidence in the integrity of affected records.

5. Omnichannel engagement will mature into governed, context-aware communication

Life sciences engagement strategies will mature from producing more digital content to governing which approved information reaches each audience and context. The opportunity spans healthcare-professional education, patient-support administration, and communications with clinical research sites. Relevance matters, but so do accuracy, accessibility, privacy, and consistency across channels.

The emerging model will combine reusable, approved content with audience preferences, language, channel, and jurisdictional controls. AI may help prepare drafts or identify appropriate assets, but publication will need to remain subject to the required medical, legal, and regulatory review processes. Commercial, medical, and research communications must retain their distinct purposes and controls. Success will depend less on maximizing message volume and more on making each interaction useful and appropriate.

The 2027 imperative: Make innovation dependable

The common thread across these predictions is not a single technology. It is the ability to connect information, decisions, and accountability. AI needs trusted source material. Supply chain intelligence needs dependable partner data. Resilience needs service context and controlled change. Effective engagement needs approved content and clear boundaries.

For life sciences leaders, the practical starting point is a high-friction workflow with a measurable business outcome. Identify its authoritative information, map its dependencies, define the controls, and establish a baseline before introducing automation. In 2027, competitive advantage will come less from announcing the most ambitious AI vision than from making innovation dependable enough to use every day.

See how connected, governed information can support dependable operations across the life sciences value chain.

Scott Lundstrom

Scott is a long-time industry analyst, CIO, and software developer supporting complex regulated businesses in healthcare, life sciences and consumer goods. At AMR, Scott contributed to the original SCOR model, and helped launch the Top 25 Supply-Chain program. Scott founded the health industry practice at IDC Research and lead this group for 13 years. Scott also held leadership roles in research focused on AI, Cloud, SaaS, enterprise applications and analytics.